SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0000950170-24-038623
Filing Date
2024-03-29
Accepted
2024-03-29 16:03:10
Documents
18
Period of Report
2024-03-29

Document Format Files

Seq Description Document Type Size
1 PRE 14A evok-20240329.htm   iXBRL PRE 14A 1351841
2 GRAPHIC img216179722_0.jpg GRAPHIC 17621
3 GRAPHIC img216179722_1.jpg GRAPHIC 17621
4 GRAPHIC img216179722_2.jpg GRAPHIC 277806
5 GRAPHIC img216179722_3.jpg GRAPHIC 282594
6 GRAPHIC img216179722_4.jpg GRAPHIC 231514
7 GRAPHIC img216179722_5.jpg GRAPHIC 77413
  Complete submission text file 0000950170-24-038623.txt   4091284

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT evok-20240329.xsd EX-101.SCH 25985
21 EXTRACTED XBRL INSTANCE DOCUMENT evok-20240329_htm.xml XML 163801
Mailing Address 420 STEVENS AVENUE SUITE 370 SOLANA BEACH CA 92075
Business Address 420 STEVENS AVENUE SUITE 370 SOLANA BEACH CA 92075 858-345-1494
Evoke Pharma Inc (Filer) CIK: 0001403708 (see all company filings)

IRS No.: 208447886 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-36075 | Film No.: 24804107
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)